Gilder Gagnon Howe & Co. LLC Buys New Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Gilder Gagnon Howe & Co. LLC bought a new stake in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 612,235 shares of the company's stock, valued at approximately $7,371,000. Gilder Gagnon Howe & Co. LLC owned 1.92% of Delcath Systems as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in Delcath Systems during the 4th quarter worth about $66,000. Barclays PLC bought a new position in Delcath Systems during the 3rd quarter worth approximately $104,000. Jane Street Group LLC bought a new position in shares of Delcath Systems during the 3rd quarter worth about $110,000. Private Advisor Group LLC bought a new stake in Delcath Systems during the 4th quarter worth approximately $153,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Delcath Systems during the fourth quarter valued at about $156,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. HC Wainwright lifted their price target on Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. Craig Hallum boosted their price objective on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Friday, January 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of "Moderate Buy" and an average target price of $22.75.

Delcath Systems Trading Up 3.0 %

Shares of NASDAQ DCTH traded up $0.36 during midday trading on Friday, reaching $12.44. 185,424 shares of the company were exchanged, compared to its average volume of 355,861. Delcath Systems, Inc. has a 1 year low of $5.30 and a 1 year high of $16.97. The stock has a fifty day simple moving average of $12.45 and a 200 day simple moving average of $12.47. The stock has a market cap of $416.04 million, a P/E ratio of -9.23 and a beta of 0.85.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The business had revenue of $15.10 million for the quarter, compared to analysts' expectations of $14.96 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. During the same quarter last year, the company posted ($0.48) earnings per share. As a group, analysts forecast that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.